Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136190

Published: 2020

Journal Articles

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Lynda M. Vrooman, MD, Yael Flamand, MS, Victoria Koch, BS, Melissa A. Burns, MD, Sarah M. Cronholm, BA, Sarah K. Hunt, BS, MPH, Peter D. Cole, MD, Lisa M. Gennarini, MD, Justine M. Kahn, MDMSc, Kara M. Kelly, MD, Bruno Michon, MD FRCPC, Donna S. Neuberg, ScD, Andrew E. Place, MDPhD, Thai Hoa Tran, MD, Jennifer J.G. Welch, MD, Kristen E. Stevenson, MS, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138840

Published: 2020

Journal Articles

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort

Qianqian Zhu, PhD, Song Yao, PhD, Peter D Cole, MD, Justine M. Kahn, MD MS, Marian H. Harris, MD PhD, Emily Schiller, MS, Uma Athale, MDMBBS,MSc, Luis A. Clavell, MD, Caroline Laverdiere, MD FRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Kara M. Kelly, MD

Blood (2019) 134 (Supplement_1): 3811.

https://doi.org/10.1182/blood-2019-126814

Published: 2019

Journal Articles

Hispanic Race Is Associated with Increased Risk of Severe Sepsis in 1913 Hospitalizations of Children with AML and Infection

Beth Savage, MSN, ANP, Peter D Cole, MD, Charlotte Thomas-Hawkins, PhD RN, Jerod Stapleton, PhD, Pamela de Cordova, PhD RN-BC, Linda Flynn, PhD RN, FAAN

Blood (2019) 134 (Supplement_1): 1327.

https://doi.org/10.1182/blood-2019-123534

Published: 2019

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Uma H. Athale, MD, M.Sc., Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Menachem Spira, Peter D. Cole, MD, Barbara L Asselin, MD, Luis A. Clavell, MD, Kara M. Kelly, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 1278.

https://doi.org/10.1182/blood.V130.Suppl_1.1278.1278

Published: 2017

Journal Articles

Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group

Peter D Cole, MD, Menachem Spira, MD, Kathleen M McCarten, MD, Terzah M Horton, MD, Quinglin Pei, PhD, Monika Metzger, Richard A Drachtman, MD, Kara M. Kelly, MD

Blood (2017) 130 (Supplement 1): 2798.

https://doi.org/10.1182/blood.V130.Suppl_1.2798.2798

Published: 2017

Journal Articles

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Kara M. Kelly, MD, Elena Ladas, PhD, Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Meiko Lin, MA, Peter D Cole, MD, Manuela Orjuela, MD ScM, Uma Athale, Luis A. Clavell, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Barbara L Asselin, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 2549.

https://doi.org/10.1182/blood.V130.Suppl_1.2549.2549

Published: 2017

Journal Articles

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Blood (2016) 128 (22): 175.

https://doi.org/10.1182/blood.V128.22.175.175

Published: 2016

Journal Articles

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

Blood (2016) 128 (22): 1729.

https://doi.org/10.1182/blood.V128.22.1729.1729

Published: 2016

Journal Articles

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Uma H. Athale, MD, M.Sc., Maneka Puligandla, MS, Kristen E. Stevenson, MS, Barbara L. Asselin, MD, Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, Sc.D., Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2016) 128 (22): 761.

https://doi.org/10.1182/blood.V128.22.761.761

Published: 2016

Journal Articles

Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001

Peter D. Cole, MD, Traci M. Blonquist, MS, Veena Vijayanathan, PhD, Donna S. Neuberg, Sc.D., Lynda M. Vrooman, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Yaron Finkelstein, MD

Blood (2015) 126 (23): 251.

https://doi.org/10.1182/blood.V126.23.251.251

Published: 2015

Journal Articles

Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Maria Luisa Sulis, MD, Traci M. Blonquist, MS, Uma H. Athale, MD, M.Sc., Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Donna S Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 249.

https://doi.org/10.1182/blood.V126.23.249.249

Published: 2015

Journal Articles

Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Marian H. Harris, MD PhD, Traci M. Blonquist, MS, Uma H. Athale, MD, M.Sc., Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Donna S. Neuberg, Sc.D., Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 2613.

https://doi.org/10.1182/blood.V126.23.2613.2613

Published: 2015

Journal Articles

Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group

Kara M. Kelly, MD, Peter D. Cole, MD, Lu Chen, PhD, Kenneth B Roberts, MD, David C. Hodgson, MD, Kathleen McCarten, MD, Steve Y Cho, MD, Cindy Schwartz, MD

Blood (2015) 126 (23): 3927.

https://doi.org/10.1182/blood.V126.23.3927.3927

Published: 2015

Journal Articles

AHOD0321: A COG Phase 2 Study of Weekly Gemcitabine and Vinorelbine for Children with Recurrent or Refractory Hodgkin Disease.

Peter D. Cole, MD, Tanya M. Trippett, MD, Richard A. Drachtman, MD, Pedro de Alarcon, MD, Lu Chen, Cindy L. Schwartz, MD

Blood (2007) 110 (11): 2318.

https://doi.org/10.1182/blood.V110.11.2318.2318

Published: 2007

Journal Articles

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Peter D. Cole, MD, Richard A. Drachtman, MD, Angela K. Smith, Margaret Masterson, MD, John Glod, Md, PhD, Barton A. Kamen, MD, PhD

Blood (2006) 108 (11): 1860.

https://doi.org/10.1182/blood.V108.11.1860.1860

Published: 2006

Journal Articles

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Peter D. Cole, MD, Richard A. Drachtman, MD, Margaret Masterson, MD, Angela Shenkerman, APN, Angela K. Smith, Benadette Makori, Barton A. Kamen, MD, PhD

Blood (2004) 104 (11): 1950.

https://doi.org/10.1182/blood.V104.11.1950.1950

Published: 2004

NARROW

Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort

Hispanic Race Is Associated with Increased Risk of Severe Sepsis in 1913 Hospitalizations of Children with AML and Infection

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001

Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group

AHOD0321: A COG Phase 2 Study of Weekly Gemcitabine and Vinorelbine for Children with Recurrent or Refractory Hodgkin Disease.

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only